Improving the identification of high-risk non-metastatic castration-resistant prostate cancer patients in clinical practice

Alina Rosinha; Carlos Rabaça; Fernando Calais; João Moreira Pinto; João Vasco Barreira; Ricardo Fernandes; Rodrigo Ramos; Ana Cristina Fialho; José Palma dos Reis

doi:10.3389/fonc.2023.1266369

Improving the identification of high-risk non-metastatic castration-resistant prostate cancer patients in clinical practice

Alina Rosinha, Carlos Rabaça, Fernando Calais, João Moreira Pinto, João Vasco Barreira, Ricardo Fernandes, Rodrigo Ramos, Ana Cristina Fialho, José Palma dos Reis^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

3 Downloads

Abstract

Non-metastatic castration-resistant prostate cancer (nmCRPC) represents a challenging disease state in prostate cancer care. nmCRPC patients with a high risk of progression to metastatic disease who are identified by a prostate-specific antigen doubling time (PSADT) ≤10 months are eligible for treatment with the novel androgen receptor inhibitors (ARIs), shown to delay disease progression and extend survival. However, nmCRPC is often unexploited in clinical practice due to a lack of standardization in the methodology and in the tools used for its identification. In this article, a group of Urology and Oncology specialists with acknowledged expertise in prostate cancer reviews the state of the art in the management of high-risk nmCRPC patients, identifies gaps and unmet needs, and proposes strategies to optimize the identification of this patient subgroup in the clinical practice and improve their health outcomes.

Original language	English
Article number	1266369
Number of pages	7
Journal	Frontiers in Oncology
Volume	13
DOIs	https://doi.org/10.3389/fonc.2023.1266369
Publication status	Published - 2023

Keywords

High-risk
identification
Non-metastatic castration-resistant prostate cancer
Prostate-specific antigen
Prostate-specific antigen doubling time
Standardization

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3389/fonc.2023.1266369Licence: CC BY

94211370Final published version, 1.48 MBLicence: CC BY

http://hdl.handle.net/10400.14/44029Licence: CC BY

Cite this

@article{6b1b047543c04dba9e272afbd7ca4d08,

title = "Improving the identification of high-risk non-metastatic castration-resistant prostate cancer patients in clinical practice",

abstract = "Non-metastatic castration-resistant prostate cancer (nmCRPC) represents a challenging disease state in prostate cancer care. nmCRPC patients with a high risk of progression to metastatic disease who are identified by a prostate-specific antigen doubling time (PSADT) ≤10 months are eligible for treatment with the novel androgen receptor inhibitors (ARIs), shown to delay disease progression and extend survival. However, nmCRPC is often unexploited in clinical practice due to a lack of standardization in the methodology and in the tools used for its identification. In this article, a group of Urology and Oncology specialists with acknowledged expertise in prostate cancer reviews the state of the art in the management of high-risk nmCRPC patients, identifies gaps and unmet needs, and proposes strategies to optimize the identification of this patient subgroup in the clinical practice and improve their health outcomes.",

keywords = "High-risk, identification, Non-metastatic castration-resistant prostate cancer, Prostate-specific antigen, Prostate-specific antigen doubling time, Standardization",

author = "Alina Rosinha and Carlos Raba{\c c}a and Fernando Calais and Pinto, {Jo{\~a}o Moreira} and Barreira, {Jo{\~a}o Vasco} and Ricardo Fernandes and Rodrigo Ramos and Fialho, {Ana Cristina} and {Palma dos Reis}, Jos{\'e}",

note = "Publisher Copyright: Copyright {\textcopyright} 2024 Rosinha, Raba{\c c}a, Calais, Pinto, Barreira, Fernandes, Ramos, Fialho and Palma dos Reis.",

year = "2023",

doi = "10.3389/fonc.2023.1266369",

language = "English",

volume = "13",

journal = "Frontiers in Oncology",

issn = "2234-943X",

publisher = "Frontiers Media SA",

}

TY - JOUR

T1 - Improving the identification of high-risk non-metastatic castration-resistant prostate cancer patients in clinical practice

AU - Rosinha, Alina

AU - Rabaça, Carlos

AU - Calais, Fernando

AU - Pinto, João Moreira

AU - Barreira, João Vasco

AU - Fernandes, Ricardo

AU - Ramos, Rodrigo

AU - Fialho, Ana Cristina

AU - Palma dos Reis, José

PY - 2023

Y1 - 2023

N2 - Non-metastatic castration-resistant prostate cancer (nmCRPC) represents a challenging disease state in prostate cancer care. nmCRPC patients with a high risk of progression to metastatic disease who are identified by a prostate-specific antigen doubling time (PSADT) ≤10 months are eligible for treatment with the novel androgen receptor inhibitors (ARIs), shown to delay disease progression and extend survival. However, nmCRPC is often unexploited in clinical practice due to a lack of standardization in the methodology and in the tools used for its identification. In this article, a group of Urology and Oncology specialists with acknowledged expertise in prostate cancer reviews the state of the art in the management of high-risk nmCRPC patients, identifies gaps and unmet needs, and proposes strategies to optimize the identification of this patient subgroup in the clinical practice and improve their health outcomes.

AB - Non-metastatic castration-resistant prostate cancer (nmCRPC) represents a challenging disease state in prostate cancer care. nmCRPC patients with a high risk of progression to metastatic disease who are identified by a prostate-specific antigen doubling time (PSADT) ≤10 months are eligible for treatment with the novel androgen receptor inhibitors (ARIs), shown to delay disease progression and extend survival. However, nmCRPC is often unexploited in clinical practice due to a lack of standardization in the methodology and in the tools used for its identification. In this article, a group of Urology and Oncology specialists with acknowledged expertise in prostate cancer reviews the state of the art in the management of high-risk nmCRPC patients, identifies gaps and unmet needs, and proposes strategies to optimize the identification of this patient subgroup in the clinical practice and improve their health outcomes.

KW - High-risk

KW - identification

KW - Non-metastatic castration-resistant prostate cancer

KW - Prostate-specific antigen

KW - Prostate-specific antigen doubling time

KW - Standardization

UR - http://www.scopus.com/inward/record.url?scp=85184263256&partnerID=8YFLogxK

U2 - 10.3389/fonc.2023.1266369

DO - 10.3389/fonc.2023.1266369

M3 - Article

C2 - 38322282

AN - SCOPUS:85184263256

SN - 2234-943X

VL - 13

JO - Frontiers in Oncology

JF - Frontiers in Oncology

M1 - 1266369

ER -

Improving the identification of high-risk non-metastatic castration-resistant prostate cancer patients in clinical practice

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

CIIS: Center for Interdisciplinary Research in Health

Cite this

Improving the identification of high-risk non-metastatic castration-resistant prostate cancer patients in clinical practice

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Projects

CIIS: Center for Interdisciplinary Research in Health

Cite this